Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.

Antibody-drug conjugates (ADCs) are emerging therapeutic agents in the treatment of cancer, and various conjugation strategies and chemical linkers have been developed to efficiently construct ADCs. Despite previous extensive efforts for improving conjugation efficiency and ADC homogeneity, most ADC linkers developed to date load only single payloads. Branched linkers that can load multiple payload molecules have yet to be fully explored. It is logical to envisage that a multi-loading strategy allows for increase in drug-to-antibody ratio (DAR) with less chemical or enzymatic modification to the antibody structure compared to traditional linear linkers, leading to efficient ADC construction, minimal destabilization of the antibody structure, and enhanced ADC efficacy. Herein, we report that the branched linkers we designed can be quantitatively installed on an anti-HER2 monoclonal antibody by microbial transglutaminase (MTGase)-mediated conjugation without impairing its antigen binding affinity, enabling modular installation of payload molecules and construction of homogeneous ADCs with increased DARs (up to 8). An anti-HER2 antibody-monomethyl auristatin F conjugate constructed using our branched linkers showed greater in vitro cytotoxicity against HER2-expressing breast cancer cell lines than that consisting of linear linkers, demonstrating the effectiveness of the branched linker-based payload delivery. Our finding demonstrates that enzymatic ADC construction using branched linkers is a promising strategy, which may lead to innovative cancer therapeutics.

[1]  Mark E. B. Smith,et al.  Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody , 2017 .

[2]  Matthew R. Levengood,et al.  Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates , 2016, Angewandte Chemie.

[3]  G. Adams,et al.  DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents , 2016, Molecules.

[4]  Z. An,et al.  Antibody-drug conjugates: recent advances in conjugation and linker chemistries , 2016, Protein & Cell.

[5]  Daniel A. Richards,et al.  Dual modification of biomolecules. , 2016, Organic & biomolecular chemistry.

[6]  Feng Jiang,et al.  Linkers Having a Crucial Role in Antibody–Drug Conjugates , 2016, International journal of molecular sciences.

[7]  Nikolaos Diamantis,et al.  Antibody-drug conjugates—an emerging class of cancer treatment , 2016, British Journal of Cancer.

[8]  P. Polakis.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[9]  R. Halcomb,et al.  Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. , 2015, Molecular pharmaceutics.

[10]  M. Marelli,et al.  Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. , 2015, Bioconjugate chemistry.

[11]  P. Burke,et al.  Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index , 2015, Nature Biotechnology.

[12]  F. V. van Delft,et al.  Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. , 2015, Bioconjugate chemistry.

[13]  Enrique Miranda,et al.  A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy , 2015, Nature Communications.

[14]  E. Fischer,et al.  Microbial Transglutaminase and c‐myc‐Tag: A Strong Couple for the Functionalization of Antibody‐Like Protein Scaffolds from Discovery Platforms , 2015, Chembiochem : a European journal of chemical biology.

[15]  E. Fischer,et al.  Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models. , 2015, Molecular pharmaceutics.

[16]  S. Owen,et al.  Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.

[17]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[18]  Xue-jun Fan,et al.  Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation , 2014, Breast Cancer Research.

[19]  Kelly A. Schwarz,et al.  Auristatin antibody drug conjugate physical instability and the role of drug payload. , 2014, Bioconjugate chemistry.

[20]  S. Caddick,et al.  Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment. , 2014, Bioconjugate chemistry.

[21]  E. Fischer,et al.  Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. , 2014, Bioconjugate chemistry.

[22]  C. J. Murray,et al.  Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. , 2014, Bioconjugate chemistry.

[23]  Peter G Schultz,et al.  A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.

[24]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[25]  M. Dorywalska,et al.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.

[26]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[27]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[28]  P. Senter,et al.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2012, Nature Biotechnology.

[29]  M. Sliwkowski,et al.  Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.

[30]  A. Younes,et al.  Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.

[31]  M. Honer,et al.  Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. , 2010, Angewandte Chemie.

[32]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[33]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[34]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[35]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[36]  M. Goto,et al.  An enzymatic method for site-specific labeling of recombinant proteins with oligonucleotides. , 2007, Chemical communications.

[37]  Jennifer A. Prescher,et al.  A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. , 2004, Journal of the American Chemical Society.

[38]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[39]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.

[40]  P. Trail,et al.  Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. , 2002, Bioconjugate chemistry.

[41]  P. Trail,et al.  Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages. , 2002, Bioorganic & medicinal chemistry letters.

[42]  Y. Takahara,et al.  Further studies on the site-specific protein modification by microbial transglutaminase. , 2001, Bioconjugate chemistry.

[43]  F. Spener,et al.  Use of microbial transglutaminase for the enzymatic biotinylation of antibodies. , 2000, Journal of immunological methods.

[44]  P. Senter,et al.  Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. , 2012, Methods in enzymology.

[45]  P. F. Nielsen,et al.  Transglutaminase‐mediated methods for site‐selective modification of human growth hormone , 2010, Biopolymers.

[46]  R. Schibli,et al.  Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. , 2008, Bioconjugate chemistry.